Skip to main content
Premium Trial:

Request an Annual Quote

Caliper Posts Sharp Increase in Q3 Revenue (Thanks, Zymark!) Amid Widened Loss

NEW YORK, Nov. 6 (GenomeWeb News) - Caliper Technologies today reported a significant increase in third-quarter - largely as the result of its acquisition of Zymark this summer - atop narrowed R&D spending widened net loss.


Total revenue for the period ended Sept. 30 jumped to $16.5 million from $6.6 million year over year. Meantime, R&D costs in the third quarter fell to $9 million from $10.9 million over the same period last year.


Still, net loss grew to $10.1 million, or $.37 per share, from $9.4 million, or $.38 per share, in the third quarter 2002.


Caliper said it had around $5 million in cash and equivalents as of Sept. 30.


As GenomeWeb News reported in June, Caliper acquired closely held lab automation firm Zymark from its parent firm, the Berwind Company, for $57 million cash and 3.15 million shares of Caliper stock.


Caliper said Zymark's lab-automation product line and sales force would provide a broader commercial outlet for its own microfluidic LabChip platform.


In July, Zymark became a wholly owned subsidiary of Caliper, and continues to sell products under its own name. The new company's headquarters is based in Hopkinton, Mass.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.